Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Nov;18(11):e70042.
doi: 10.1111/irv.70042.

Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023-2024 Season

Takeyuki Goto  1 , Naoki Kawai  2   3 , Takuma Bando  2   4 , Yoshio Takasaki  5 , Shizuo Shindo  6 , Tomonori Sato  1 , Naoki Tani  7 , Yong Chong  8 , Hideyuki Ikematsu  2   9
Affiliations
Observational Study

Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023-2024 Season

Takeyuki Goto et al. Influenza Other Respir Viruses. 2024 Nov.

Abstract

Background: Clinical data on patients infected with influenza B Victoria (BV) after the approval of baloxavir is lacking.

Methods: This observational study of the Japanese 2023-2024 influenza season analyzed data from 25 outpatients with A(H1N1)pdm09, 36 with A(H3N2), and 65 with BV. Viral samples were collected before and after administering an antiviral (70 patients received baloxavir and 56 received a neuraminidase inhibitor), on days 1, 5, and 10. Isolated viruses after culturing were amplified using RT-PCR and sequenced to detect mutations of concern, including acidic protein (PA)-amino acid (AA) E23X/I38X for influenza A and M34X/I38X for BV. Fever and symptoms were tracked via self-reporting diaries.

Results: No PA-AA-substituted virus was detected from 126 pre-treatment samples. In the baloxavir cohort, one (7.1%, 1/14) PA I38F-substituted A(H1N1)pdm09 and two (11.1%, 2/18) PA I38T-substituted A(H3N2) viruses were isolated on day 5 but not on day 10. No (0%, 0/37) PA-AA-substituted BV was detected on day 5 or after. The virus isolation rate on day 5 was higher among patients with BV than with influenza A in both baloxavir (35.1% vs. 14.3% for A(H1N1)pdm09 and 16.7% for A(H3N2)) and oseltamivir-treated patients (44.4% vs. 0% for A(H1N1)pdm09 and 33.3% for A(H3N2)). Patients with PA-AA-substituted influenza A after baloxavir administration did not have longer fever duration than those without virus isolation or with wild-type virus on day 5, for both A(H1N1)pdm09 and A(H3N2).

Conclusions: Baloxavir-resistant variants were not detected in influenza BV before treatment, as with A. The emergence of PA-AA-substituted influenza A after baloxavir administration was temporal and did not cause prolonged symptoms. No baloxavir-resistant BV variants were observed after baloxavir administration.

Keywords: B Victoria; baloxavir; influenza; laninamivir; oseltamivir; variant.

PubMed Disclaimer

Conflict of interest statement

H. Ikematsu has previously received honoraria from Shionogi & Co., Ltd., and Daiichi Sankyo Co., Ltd. for medical advice and lectures.

References

    1. National Institute of Infectious Diseases ., 2024. Weekly reports of influenza virus isolation/detection, accessed September 5, 2024,https://kansen‐levelmap.mhlw.go.jp/Byogentai/Pdf/data127e.pdf.
    1. Hayden F. G., Sugaya N., Hirotsu N., et al., “Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents,” The New England Journal of Medicine 379 (2018): 913–923. - PubMed
    1. Ison M. G., Portsmouth S., Yoshida Y., et al., “Early Treatment With Baloxavir Marboxil in High‐Risk Adolescent and Adult Outpatients With Uncomplicated Influenza (CAPSTONE‐2): A Randomised, Placebo‐Controlled, Phase 3 Trial,” Lancet Infectious Diseases 20 (2020): 1204–1214. - PubMed
    1. Hirotsu N., Sakaguchi H., Sato C., et al., “Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes,” Clinical Infectious Diseases 71 (2020): 971–981. - PMC - PubMed
    1. Chong Y., Kawai N., Tani N., et al., “Virological and Clinical Outcomes in Outpatients Treated With Baloxavir or Oseltamivir: A Japanese Multicenter Study in the 2019–2020 Influenza Season,” Antiviral Research 192 (2021): 105092. - PubMed

Publication types

MeSH terms

LinkOut - more resources